Hexarelin 5mg Growth Factors

The strongest GH peak in class.

The most potent GH spike in its class. Second-generation secretagogue, Hexarelin triggers a massive GH release, the spike researchers come for. Demonstrated cardioprotective bonus. For those who want the maximum, no compromise.

34,00 €
Tax included • Free delivery from 119€
+1,70 € cashback on this orderCreate your account: 10% off your first order and +1,70 € cashback.
Minimum quantity: 11
Tax included • Free delivery from 119€
+1,70 € cashback on this orderCreate your account: 10% off your first order and +1,70 € cashback.
Only 3 leftships Thursday, November 19
  • In stock in France
  • Ordered with its water: shipped in a magnetic box
Subscription
30,60 €-10 %instead of 34,00 €

10% off every deliveryPause, skip or cancel in 1 clickNo commitment, no hidden fees

No automatic charge: pay for each delivery by card, in Bitcoin (an extra 5% off), or by bank transfer from €100

Your complete kit

The vial alone cannot be used as is. Add what you need to prepare it:

5mg vialIncluded

Research Use Only (RUO) · Prohibited for human or veterinary use.

Key facts

Hexarelin 5mg represents the absolute benchmark of synthetic GHRPs through its secretagogue potency. This hexapeptide His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 of 887 Da, developed in the 1990s by the teams of Romano Deghenghi and Ezio Ghigo at Mediolanum Farmaceutici, is classically described in the literature as the most potent growth hormone secretion stimulator ever synthesized for subcutaneous injection.

In detail

Beyond its raw potency on the somatotropic axis, Hexarelin stands out through a unique particularity among secretagogues: its affinity for the cardiac scavenger receptor CD36, which makes it a privileged object of study in experimental cardiology. Preclinical studies from 1999-2005 have suggested a cardioprotective potential distinct from the GH action, opening a specific research pathway around ischemia-reperfusion and post-infarction remodeling.

Atlas Lab supplies Hexarelin 5mg as a lyophilizate, for research applications exclusively. Strict RUO — not intended for human, veterinary, diagnostic or therapeutic use. The exceptional potency of this molecule imposes experimental rigor superior to other GHRPs in dose and kinetics management.

Protocol and preparation

Reconstitution for this format (5 mg)Standard volumes used in laboratory settings
Water addedConcentrationReading marker
1 ml5 mg/ml40 UI = 2 mg
2 ml2,5 mg/ml40 UI = 1 mg

The volume of water does not change the product, only its concentration. Introduce the water slowly along the vial wall, never directly onto the lyophilisate, then swirl without shaking. Markers given on a 1 ml syringe graduated in 100 units.

  1. Asepsis

    Disinfect surfaces and stoppers (70% alcohol).

  2. Solvent

    Draw the required volume of bacteriostatic water.

  3. Introduction

    Inject gently against the vial wall (avoid direct jet on powder).

  4. Solubilization

    Roll the vial gently. Do not shake vigorously (degradation risk).

Solution storage Once reconstituted: 2-8°C (refrigerator).

Warning Theoretical tool for chemical handling. Does not constitute medical advice.

Open the dilution calculator
What is normal on arrivalThe observations that worry customers, and are not defects
  • The amount of powder looks tiny. A lyophilisate takes up a few millimetres at the bottom of the vial, sometimes just a translucent film. The stated weight is there.
  • The powder is compact, stuck to the wall or to the stopper. Transport moves the freeze-dried cake around. It changes nothing to reconstitution.
  • The vial carries no individual label. That is our standard packaging, not a downgraded vial.
  • After reconstitution, deposits or filaments appear. This is common, especially with small molecules. Let it settle and roll the vial between your palms, never shake it.
  • The parcel is plain. Nothing on the outside indicates the contents or the brand name.

What is not normal: a cracked vial, an uncrimped cap or a stopper that moves, powder that has liquefied or changed colour. In those specific cases, write to us with a photo and we take the vial back.

Reconstitution protocols documented in the research literature recommend adding 2 ml of sterile bacteriostatic water (0.9% benzyl alcohol) to a 5 mg vial, producing a solution at 2.5 mg per milliliter, i.e. 2500 mcg/ml. This concentration facilitates experimental doses within the 100-300 mcg range per injection with a standard 29G 1ml insulin syringe (4-12 IU on the graduation).

The pharmacokinetics of Hexarelin is characterized by a Tmax of 15-30 minutes after subcutaneous injection, a GH peak reaching its maximum at 30-45 minutes, and a plasma half-life of approximately 55 minutes. The total physiological duration of action is within the 90-120 minute window post-injection. Research protocols involving multiple-injection models recommend intervals of at least 3-4 hours between two administrations to allow partial resensitization of GHS-R1a.

The experimental doses commonly reported in animal models and short-duration clinical studies are between 1 and 2 mcg per kilogram body weight, approximately 75-150 mcg for a 75 kg subject. Some research protocols used higher doses (up to 4 mcg/kg), but Arvat 1997 studies showed saturation of the GH response beyond 2 mcg/kg, rendering higher doses pharmacologically useless and increasing the risk of rapid desensitization.

Chronic schemes reported in the literature typically alternate active periods of 4-6 weeks with 2-4 week pauses to allow recovery of GHS-R1a receptor sensitivity. The desensitization documented by Broglio 2002 after 16 days of twice-daily administration imposes this cyclicity stricter than for Ipamorelin or GHRP-6. Some protocols explore weekly alternation with Ipamorelin to preserve sensitivity without completely interrupting administration.

Association with a GHRH analog such as CJC-1295 DAC, Mod GRF 1-29 or Sermorelin produces a synergistic response superior to the sum of individual effects. Typical protocols use CJC-1295 DAC 1-2 mg/week plus Hexarelin 100-150 mcg 2-3x/day. The combination of Hexarelin plus CJC-1295 without DAC (Mod GRF 1-29) is also documented, with both molecules injected simultaneously 20-30 minutes before bedtime or in post-exercise period. Injection performed on an empty stomach (90 minutes without food, particularly without carbohydrates) optimizes the GH response by avoiding inhibition by insulin and post-prandial free fatty acids.

Technical data

Reconstitution
2 ml d'eau → 2,5 mg/ml. 4 UI = 100 mcg ; 12 UI = 300 mcg.
Peptide sequence
His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH2
Molecular formula
C47H58N12O6
Molecular weight
887 g/mol
CAS number
140703-51-1
Physical form
Poudre lyophilisée
Recommended solubility
Eau bactériostatique, NaCl 0,9%
Storage conditions
Au réfrigérateur (+2 à +8 °C), à l'abri de la lumière. En poudre, possible au congélateur pour une conservation longue. Une fois préparé : réfrigérateur, jamais au congélateur.
Use
Research reagent, in vitro only (RUO)

Storage & handling

Before reconstitution, the lyophilized vial of Hexarelin 5mg must be stored between 2 and 8 degrees Celsius, in its original packaging, away from direct light and any heat source. Under these conditions, the lyophilizate stability is ensured for 24 to 36 months from the manufacturing date. Prolonged storage at ambient temperature (>25 degrees Celsius) must remain exceptional and not exceed 72 hours; beyond that, a risk of degradation and potency loss exists.

After reconstitution with sterile bacteriostatic water, the aqueous Hexarelin solution remains stable for approximately 30 days at 2-8 degrees Celsius. This duration approaches that observed for Ipamorelin and GHRP-6, slightly superior to the 14-21 days documented for Sermorelin due to the superior stability conferred by the D-methylation of Trp2. Prolonged conservation beyond 30 days remains conceivable for research applications but remains discouraged beyond 45-60 days due to progressive non-enzymatic degradation (Trp oxidation, peptide bond hydrolysis in aqueous environment).

Freezing at -20 degrees Celsius or less significantly extends the stability of the reconstituted solution, up to 90-120 days in optimal conditions. However, each freeze-thaw cycle partially degrades the molecule and must be avoided. Best practice is to aliquot the reconstituted solution into portions corresponding to 3-5 days of experimental use, then freeze the aliquots individually. The thawed multi-dose vial is then used for a maximum of 30 days in refrigeration at 2-8 degrees Celsius.

Protection against light is important but non-critical for Hexarelin, less photosensitive than peptides containing melanotropin or exposed tyrosine residues. Opaque packaging or storage in a closed refrigerator drawer suffices in most configurations. On the other hand, protection against intense mechanical agitation remains essential: never shake the vial violently during reconstitution. Gentle rotation between palms or slow tilting allows lyophilizate dissolution without denaturing the hexapeptide structure.

Any solution presenting a color change (normally colorless and clear), a precipitate, or particles in suspension must be immediately discarded. Visual inspection before each sampling is a mandatory practice in research context. Atlas Lab provides detailed recommendations for rigorous experimental traceability.

Mechanism of action

Hexarelin belongs to the GHRP (Growth Hormone Releasing Peptides) family and acts primarily as an agonist of the GHS-R1a receptor (Growth Hormone Secretagogue Receptor type 1a), the endogenous ghrelin receptor located in the anterior pituitary, hypothalamus (arcuate nucleus), and some peripheral tissues. This action activates a Gq11-phospholipase C-IP3-calcium cascade that triggers exocytosis of GH-containing granules in somatotroph cells.

The hexapeptide presents two critical structural modifications that explain its potency superior to first-generation GHRPs. The D-methylation of Trp at position 2 protects against enzymatic degradation by serum peptidases, extending plasma half-life to approximately 55 minutes (versus 15-20 minutes for GHRP-6). The D-phenylalanine at position 5 increases GHS-R1a affinity by a factor of 2-3 compared to GHRP-6, explaining the increased potency documented in the studies of Imbimbo 1994 (European Journal of Endocrinology) and Ghigo 1994 (Journal of Clinical Endocrinology and Metabolism).

The most studied particularity of Hexarelin remains its binding to the CD36 receptor, a scavenger receptor member of the class B scavenger receptor family, massively expressed in myocardium, macrophages, adipocytes and platelets. Tivesten and collaborators demonstrated in 2000 (Endocrinology) that Hexarelin binds CD36 with nanomolar affinity, triggering signaling independent of GHS-R1a involving the PI3K-Akt-eNOS pathway and potentially cardioprotective mechanisms. Locatelli 1999 (Circulation) had suggested in ischemia-reperfusion models in rats a reduction of infarct size.

In synergy with GHRH analogs (CJC-1295, Sermorelin, Mod GRF), Hexarelin produces an amplified GH response beyond the arithmetic sum of the two molecules, reflecting the dual mechanism activated. However, its propensity to induce GHS-R1a receptor desensitization is more marked than that of Ipamorelin or GHRP-6, which influences the cycling protocols observed in publications.

Studies and references

The clinical and preclinical corpus of Hexarelin covers approximately thirty years of publications since its discovery. The first pivotal studies, signed Imbimbo in 1994 in European Journal of Endocrinology, established in 12 healthy male volunteers that a single dose of 2 mcg/kg subcutaneously generated a plasma GH peak approximately six times greater than GHRH-29 at equivalent dose. Ghigo 1994 (Journal of Clinical Endocrinology and Metabolism) then compared Hexarelin to GHRP-6 in 16 healthy subjects, confirming a potency 2.5 times superior with a GH peak reached at 30-45 minutes post-injection.

Arvat and collaborators published in 1997 (Journal of Clinical Endocrinology and Metabolism) a dose-response study in 20 healthy subjects showing saturation of the GH response around 2 mcg/kg, with a plateau beyond which increasing doses no longer produced proportional elevation. This study provided a pharmacological basis for sizing subsequent protocols. Korbonits 1998 (Journal of Endocrinology) extended these observations to aging populations by showing that Hexarelin partially restored the somatotropic response in subjects over 65 years old whose GH axis was declining.

The cardiovascular pathway was inaugurated by Locatelli and collaborators in 1999 (Circulation) in an ischemia-reperfusion model in rats, where administration of Hexarelin before and after coronary occlusion was associated with a reduction of infarct size of approximately 30% compared to control. Tivesten 2000 (Endocrinology) identified CD36 as mediator of this action and demonstrated that GHS-R1a knockout rats retained the cardioprotective effect of Hexarelin, confirming the independence of the GH pathway.

Bisi 1999 (European Journal of Endocrinology) suggested positive inotropic effects in heart failure patients in a short-duration phase 2 study, but therapeutic development was not pursued beyond. Broglio 2002 (Journal of Endocrinological Investigation) characterized the kinetics of GHS-R1a desensitization after chronic administration in 8 subjects, documenting an attenuation of the GH response of approximately 40% after 16 days of twice-daily administration, which influenced subsequent cycling protocols in the literature.

Ghigo 2005 (Hormone Research) published a review synthesizing 250+ publications on the hexapeptide, recalling that no commercial therapeutic development had succeeded despite the remarkable pharmacological profile, mainly due to industrial preferences for less potent but more selective molecules like Ipamorelin or for long half-life GHRH analogs like Tesamorelin. Hexarelin nevertheless remains a precious experimental tool for studying GHS-R1a/CD36 signaling and cardiovascular models.

  1. 1
    Libération GHGrowth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man

    Ghigo E, Arvat E, Gianotti L, et al. · Journal of Clinical Endocrinology & Metabolism · 1994

  2. 2
    Dose-réponseGrowth hormone-releasing activity of hexarelin in humans. A dose-response study

    Imbimbo BP, Mant T, Edwards M, et al. · European Journal of Clinical Pharmacology · 1994

The listed studies are provided for documentation and research purposes only. They do not constitute a therapeutic indication nor a recommendation for human use. This product is strictly for laboratory use only (RUO).

Similar peptides

In the GHRP family, Hexarelin occupies a distinct position that should be compared to other secretagogues to inform experimental choices. Versus GHRP-6 (Hexarelin being the improved historical precursor of GHRP-6), Hexarelin offers a potency 2-3 times superior on the GH response at equivalent dose and a prolonged half-life of 55 minutes versus 15-20 minutes. On the other hand, GHRP-6 retains a specific advantage: its marked orexigenic effect via activation of the ghrelin/NPY/AgRP pathway, useful in certain experimental appetite research models. Hexarelin induces a more modest and less constant rise in appetite.

Versus GHRP-2 (pralmorelin), Hexarelin presents equivalent or slightly superior potency, but a longer half-life. GHRP-2 reaches its plasma peak faster (Tmax 10-15 min) with shorter kinetics (half-life 20-30 min), resulting in shorter and more intense GH pulses. GHRP-2 possesses a slight elevation of cortisol and prolactin comparable to Hexarelin, but less than GHRP-6.

Versus Ipamorelin, the contrast is stark. Ipamorelin is the most selective pentapeptide of the class, with GH stimulation comparable to GHRP-6 but without elevation of cortisol, prolactin or ACTH. Hexarelin, more potent on absolute GH response, instead induces a slight rise in cortisol and prolactin (documented by Arvat 1997) and faster receptor desensitization. The choice between the two molecules thus depends on the potency/selectivity compromise sought by the experimental protocol. For long chronic periods, Ipamorelin is preferred; for short windows of maximum stimulation, Hexarelin retains the advantage.

Versus MK-677 (Ibutamoren), non-peptide orally active secretagogue with a half-life of 24 hours, Hexarelin offers a more physiological pulsatile action but requires multiple daily injections. MK-677 maintains chronic elevation of GH/IGF-1 but can induce water retention, insulin resistance and hyperphagia, effects less documented with Hexarelin used in short cycles.

The unique particularity of Hexarelin concerns its affinity for CD36, not shared by Ipamorelin, GHRP-6, GHRP-2 or MK-677. This specific binding opens experimental applications in cardiology that are exclusive to Hexarelin in the peptide GHRP class. Researchers working on ischemia-reperfusion models or post-infarction myocardial remodeling find in Hexarelin a unique tool, even if Ipamorelin remains preferred for exclusively somatotropic studies.

In combination with CJC-1295 DAC (long-acting GHRH analog), Hexarelin generates a synergistic GH response comparable to that of Ipamorelin plus CJC-1295 DAC, but with superior peak intensity. In combination with CJC-1295 without DAC (Mod GRF 1-29, 30 min half-life), the synergy is also documented. However, Hexarelin's propensity for desensitization imposes stricter cycles (4-6 active weeks, 2-4 weeks pause) than the Ipamorelin plus CJC-1295 DAC combination, which better tolerates chronic continuous protocols.

Frequently asked questions

Why is Hexarelin considered the most potent GHRP?
Hexarelin's superior potency stems from two key structural modifications: D-methylation of Trp at position 2 which extends plasma half-life to 55 minutes, and D-phenylalanine at position 5 which increases GHS-R1a affinity by a factor of 2-3 compared to GHRP-6. Ghigo 1994 studies documented a GH response approximately 2.5 times superior at equivalent dose. Imbimbo 1994 observed a GH peak six times superior to GHRH-29 in 12 healthy subjects.
What is the particularity of Hexarelin on the CD36 receptor?
Hexarelin binds to the CD36 scavenger receptor with nanomolar affinity, a property not shared by Ipamorelin, GHRP-6 or MK-677. CD36 is massively expressed in myocardium, and its stimulation would trigger PI3K-Akt-eNOS signaling potentially cardioprotective. Tivesten 2000 demonstrated in GHS-R1a knockout rats that the cardioprotective effect of Hexarelin was preserved, confirming the independence of this pathway from the GH mechanism. This feature makes Hexarelin unique for experimental models in cardiology.
How to reconstitute Hexarelin 5mg?
Add 2 ml of sterile bacteriostatic water to the 5 mg vial to obtain a concentration of 2.5 mg/ml (i.e. 2500 mcg/ml). Never shake; let the liquid slowly flow on the inner wall of the vial and perform gentle rotation between palms until complete dissolution. The solution must be clear and colorless, without visible particles. Any anomaly (cloudiness, precipitate, coloration) requires discarding the solution. Then store in refrigerator between 2 and 8 degrees Celsius.
What are the doses typically used in research?
Clinical studies have generally used doses of 1 to 2 mcg per kilogram body weight, approximately 75-150 mcg for a 75 kg subject. Arvat 1997 demonstrated saturation of the GH response beyond 2 mcg/kg, rendering higher doses pharmacologically useless. Current research protocols use 100-300 mcg per injection, 2-3 times per day with intervals of at least 3-4 hours. Total daily dose rarely exceeds 600 mcg to limit receptor desensitization.
How to manage GHS-R1a receptor desensitization?
Broglio 2002 documented an attenuation of the GH response of approximately 40% after 16 days of twice-daily Hexarelin administration. Chronic protocols therefore recommend cycles of 4-6 active weeks followed by 2-4 weeks pause to allow receptor resensitization. Some approaches alternate Hexarelin and Ipamorelin on a weekly basis to maintain somatotropic stimulation without complete desensitization. Strict respect of 3-4 hour intervals between multiple injections also contributes to limiting desensitization.
Hexarelin or Ipamorelin: which choice for research?
The choice depends on the potency/selectivity compromise sought. Hexarelin offers superior GH potency and a unique pathway via CD36 relevant in experimental cardiology, but induces a slight rise in cortisol/prolactin and faster desensitization. Ipamorelin is the most selective of the class, without elevation of cortisol, prolactin or ACTH, and better tolerates chronic continuous protocols. For short windows of maximum stimulation or CD36-dependent cardiovascular studies, Hexarelin prevails; for long chronic periods oriented on pure GH axis, Ipamorelin prevails.
Why has Hexarelin no commercial therapeutic development?
Despite its remarkable pharmacological profile documented in 250+ publications, Hexarelin never led to commercial therapeutic development. Main reasons include industry preference for less potent but more selective molecules like Ipamorelin, or for long half-life GHRH analogs like Tesamorelin (only FDA-approved GHRH analog in 2010). Faster Hexarelin desensitization, slight cortisol/prolactin rise, and absence of clear specific therapeutic indication have oriented strategic choices toward other molecules.
What are the Atlas Lab quality standards for Hexarelin 5mg?
The lyophilizate is packaged in sealed borosilicate vials. Product reserved exclusively for scientific research, not intended for human use.
GH Secretagogues

Growth Factors

CJC-1295, Ipamorelin, GHRP-6: boost the GH/IGF-1 axis without steroids.

Explore the range